Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2017-09-22 09:39:59

Nse

988.00

7.10(0.72%)
Change%
52 Week Range
848.00
24.00
1,274.70
3.00
Open983.00
Day's Range882.81 - 1,078.99
Value Traded (in ₹ Cr.) 7.03

Bse

990.00

4.95(0.50%)
Change %
52 Week Range
848.50
24.00
1,259.00
3.00
Open984.00
Day's Range886.55 - 1,083.56
Value Traded (in ₹ Cr.) 1.00

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 27,798,384.00 31.09%
Mutual Funds/UTI 11,209,440.00 12.54%
FII 30,845,238.00 34.49%
Employee 0.00 0.00%
Public 11,902,841.00 13.31%
Government 0.00 0.00%
Others 5,999,622.00 6.71%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.41
Basic EPS (Rs.) 19.50
Cash EPS 29.87
BVPerShare Excl 350.93
Operating Revenue 246.62
PBDITPerShare 47.35
Dividend 4.00
NPPerShare 18.03
Current Ratio 2.06
Quick Ratio 1.77
PriceToBV 3.10
Earnings 0.01
PBDIT Margin 19.19
PBT Margin 8.59
NP Margin 7.30
Return On Assets 3.00
Retention Ratios 73.63
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,344.45
Total Expenses 2,129.99
EBITDA 423.02
PBT 189.29
PAT 161.07
Net Income 161.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,244.33
Total Expenses 1,082.98
EBITDA 106.21
PBT 108.08
PAT 108.97
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 89.35
Net worth 3,135.41
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

528.05 535.6 -1.41
526544.45

Abbott India Ltd.

4235.65 4252.25 -0.39
40014264

Ajanta Pharma Ltd.

1255 1256.6 -0.13
11881265

Albert David Ltd.

290.75 292.5 -0.6
282.5300.9

Alembic Ltd.

41.95 43.1 -2.67
38.1544.7

Alembic Pharmaceuticals Ltd.

497.35 500.35 -0.6
469.85504

Alkem Laboratories Ltd.

1803.15 1801.2 0.11
17341819
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

103.5 101.05 2.42
90121.9

Aarti Drugs Ltd.

529.3 533.85 -0.85
525540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4252.55 4269.8 -0.4
40354275

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 83.56
Cash from investing activities -1,064.38
Cash from financing activities 1,570.84
Net change in cash 591.96

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 1.32%
SBI Magnum Midcap Fund 3.21%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.57%
SBI Pharma Fund 8.30%
Tata Balanced Fund - Regular Plan 0.80%
Sundaram Select Midcap 0.83%

Greaves Cotton ties up with two others for 3-wheeler engines

Engineering major Greaves Cotton today said it has inked a pact with MLR Auto and Continental Engines to develop engines for three wheelers. The partnership aims at developing a new generation of powertrains for three-wheelers, catering to both passenger and cargo mobility solutions. The new engine would comply with BS VI emission norms using diesel, petrol, CNG as well as electric-powered solutions for last mile transportation, Greaves Cotton said in a statement. The company said it has been investing in the market and building capabilities as Indian automotive market is gearing up for a technological, regulatory and business model disruption by 2020. It is working to meet the demand for fuel agnostic, future ready solutions for the three-wheeler and small four- wheeler meant for last mile transportation market using a range of fuels including diesel, petrol, CNG and electric, the company added. Last week, the company had inked a pact with three- wheeler manufacturer Atul Auto to jointly develop power train solutions to meet BS VI norms.

21-09-2017 17:08

KNR Constructions JV wins order worth Rs 884.47 cr

Infrastructure development company KNR Constructions on Thursday said that KNR -HES-ACPL Joint Venture has bagged order worth of Rs 884.47 crore. “KNR -HES-ACPL Joint Venture has bagged order worth of Rs. 884.47 Crores towards Formation of Konda Pochamma Sagar for a capacity of 15.00 TMC near Pamulaparthi (v), Markook(M), Siddipet District - Reach - 1 from Km 0.000 to Km 5.500 with all associated components in the State of Telangana,” KNR Constructions said in a filing to the Bombay Stock Exchange. The company further said that the project is to be completed within a period of 18 months from the appointed date. Meanwhile, shares of the company closed day’s trade at Rs 212.05 apiece, down 0.75 per cent, on the Bombay Stock Exchange.

21-09-2017 16:50

Zydus gets USFDA final nod for Itraconazole Capsules

Zydus Cadila on Thursday said it has received the final approval from the US Food and Drug Administration (USFDA) to market Itraconazole Capsules 100 mg. “The drug is used to treat a variety of fungal infections and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad,” Cadila Healthcare said in a filing to the Bombay Stock. The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, shares of the company closed day’s trade at Rs 503.40 apiece, up 3.46 per cent, on the Bombay Stock Exchange.

21-09-2017 16:49

Vivimed gets Ukraine GMP nod for FDF facility in Hyderabad

Vivimed Labs said that its FDF manufacturing facility located in Jeedimetla, near Hyderabad has received Ukraine GMP Certification effective September 2017. “Vivimed Labs Limited ('Vivimed' or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that its FDF manufacturing facility located in Jeedimetla, near Hyderabad inspected in August 2017 by the Ukraine ministry of Health, has been approved and accredited with GMP Certification effective September 2017,” the company said in a filing to the Bombay Stock Exchange. Ukraine is a member Country of PICS, whose members include many European Countries. The GMP approval also includes 3 new product registrations. Meanwhile, shares of the company closed trading at Rs 142.35 apiece, up 3.08 per cent from the previous close on BSE.

21-09-2017 16:09

Safari Industries to raise Rs 51 cr via preferential issue

Safari Industries India, engages in the manufacture of plastic moulded luggage, on Thursday said that its biard has approved plan to raise funds upto Rs 51 crores through preferential issue of shares. “The board of directors of the company, at their meeting held today have amongst other matters, approved to raise funds upto Rs 51 crore by way of preferential issue,” said Safari Industries India in a filing to the Bombay Stock Exchange. The company further said that an extra-ordinary general meeting of the company will be held on 21st October 2017 at Mumbai for obtaining Shareholders approval for the preferential issue. Accordingly, the relevant date for the pricing of both the aforesaid preferential issue of equity shares is 21st September 2017, it added. Meanwhile, shares of the company were trading at Rs 1753.00 apiece, up 0.90 per cent, on the Bombay Stock Exchange at 15:10 hours.

21-09-2017 15:00

Strides bags approval for Omega-3-Acid Ethyl Esters capsules

Leading pharma major, Strides Shasun has that it has received approval from the USFDA for Omega-3-Acid Ethyl Esters capsules, a generic version of Lovaza. The US market for the generic Lovaza is approximately USD 300 million per annum, as per IMS, with five generic players including Par Pharmaceutical, an Endo International Company. “The company has partnered with Par to market the product in the US. The product to be manufactured in its flagship facility in Bangalore will be launched immediately,” the company said in a filing to the Bombay Stock Exchange. “The Omega-3-Acid Ethyl Esters capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (HTG),” it added. Meanwhile, shares of the company were trading at Rs 1019.05 apiece, up 1.08 per cent from the previous close at 11:05 hours on BSE.

20-Sep-2017 11:03 AM

Strides Shasun L - Press Release / Media Release

Strides Shasun receives USFDA Approval for Omega-3-Acid Ethyl Esters capsules

20-Sep-2017 08:42 AM

Strides Shasun L - Press Release

Strides Shasun Limited has informed the Exchange regarding a press release dated September 20, 2017, titled Strides Shasun receives USFDA Approval for Omega-3-Acid Ethyl Esters capsules.

20-Sep-2017 08:38 AM

Strides Shasun L - Shareholders meeting

Strides Shasun Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 15, 2017. Further, the company has informed the Exchange regarding voting results.

15-Sep-2017 05:19 PM

Strides Shasun L - Change in Director(s)

Strides Shasun Limited has informed the Exchange regarding Change in Director(s) of the company.

15-Sep-2017 04:21 PM

Strides Shasun L - Press Release / Media Release

Strides Shasun receives USFDA Approval for Omega-3-Acid Ethyl Esters capsules

20-Sep-2017 08:42 AM

Strides Shasun L - Press Release / Media Release

Strides Shasun receives USFDA Approval for Potassium Citrate Extended-Release Tablets

12-Sep-2017 08:46 AM

Strides Shasun L - Updates

EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore

01-Sep-2017 08:56 AM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

CHENNAI OFFICE: `Batra Centre', 3rd and 4th Floor, 28, Sardar Patel Road, Guindy,

044-43446700,22207500,,      044-22350278,

Registrar Details

Karvy Computershare Private Ltd.